GH Secretagogues Research Guide

CJC-1295 + Ipamorelin: Mechanism, Handling & Research Guide

Also known as: CJC-1295 + Ipamorelin, CJC-1295 and Ipamorelin, CJC-1295 no-DAC + Ipamorelin, CJC1295 Ipamorelin blend, GHRH analog + ghrelin mimetic combination, mod-GRF(1-29) + ipamorelin

Key Facts

CJC-1295 + Ipamorelin is a gh secretagogues research peptide. Synergistic GH secretagogue blend for body composition research. It is supplied as a lyophilized powder for laboratory and in-vitro research use only — not for human consumption.

Classification	Co-formulated growth hormone secretagogue blend: GHRH-receptor analogue (CJC-1295) plus selective GHS-R1a/ghrelin-receptor agonist (ipamorelin)
Research Half-Life	Component-dependent: CJC-1295 without DAC ~30 minutes; ipamorelin approximately 2 hours in published characterizations - the blend has no single combined value
Form	Lyophilized powder
Research Category	GH Secretagogues

What is CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is a dual-peptide formulation combining a growth hormone-releasing hormone (GHRH) analogue with a selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. These two peptides operate through complementary mechanisms: CJC-1295 (without DAC) stimulates GH release by binding GHRH receptors on pituitary somatotrophs and amplifying the baseline GH pulse, while ipamorelin activates the ghrelin receptor to initiate a separate GH release signal. When used together, research indicates a synergistic amplification of GH pulsatility that exceeds the additive effects of either peptide alone. This synergy was characterized in studies examining GHRH-GHRP combined use, where combined studies produced GH peaks 2-3 times greater than single-agent studies (Bowers et al., Endocrinology). Ipamorelin is distinguished among ghrelin mimetics by its high selectivity for GH release without significantly elevating cortisol, prolactin, or ACTH levels, as demonstrated in clinical studies (Raun et al., European Journal of Endocrinology, 1998). CJC-1295 without DAC has a half-life of approximately 30 minutes, producing acute GH pulses rather than sustained elevation. Compared to GHRP-6, which broadly activates ghrelin receptors causing appetite stimulation, ipamorelin offers cleaner GH release profiles. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This combination is widely studied by endocrinology research labs, sports medicine institutions, and body composition research centers investigating modulated GH secretagogue studies.

CJC-1295 + Ipamorelin Research Applications

In published and preclinical research, CJC-1295 + Ipamorelin has been studied across the following areas:

Growth hormone pulsatility optimization
IGF-1 level modulation
Lean mass preservation studies
Metabolic anabolic balance research

CJC-1295 + Ipamorelin in Research: Study Context

This is a two-peptide blend whose components are co-studied because they act on the two distinct, complementary arms of GH regulation: CJC-1295 (a GHRH-receptor analogue) and ipamorelin (a selective ghrelin-receptor agonist). Literature on GHRH-plus-GHRP combined use reports synergistic amplification of GH pulsatility beyond either agent alone (Teichman et al. on CJC-1295; Raun et al. on ipamorelin's selectivity), which is the rationale for combining them in research models of the GH/IGF-1 axis. For laboratory research the lyophilized blend is reconstituted with bacteriostatic water to a defined concentration such as 5.0 mg/mL total (a 10 mg vial of 5 mg CJC-1295 + 5 mg ipamorelin in 2 mL) and refrigerated at 2-8C. The product is for in-vitro and laboratory research use only, is not FDA-approved, and carries no human concentration; investigators should reference the primary literature and document each lot's Certificate of Analysis (COA).

How CJC-1295 + Ipamorelin Compares

Researchers frequently evaluate CJC-1295 + Ipamorelin alongside related compounds:

CJC-1295 + Ipamorelin vs CJC-1295 (without DAC) — The standalone short-acting GHRH-arm component of this blend, studied without the ghrelin-receptor agonist
CJC-1295 + Ipamorelin vs Ipamorelin — The standalone selective ghrelin-receptor component, studied without the GHRH-arm peptide
CJC-1295 + Ipamorelin vs CJC-1295 with DAC — Albumin-binding (DAC) long-acting GHRH analogue producing sustained elevation rather than the acute pulses of the no-DAC blend

CJC-1295 + Ipamorelin — Frequently Asked Questions

Why are CJC-1295 and ipamorelin studied together?

They engage separate receptors on the GH axis: CJC-1295 is a GHRH-receptor analogue that raises baseline GH output, while ipamorelin is a ghrelin-receptor (GHS-R1a) agonist that triggers a distinct release signal. Published GHRH-plus-GHRP combined use work reports the two pathways combine synergistically, producing larger GH pulses than either peptide alone - the basis for co-formulating them in research.

What does the literature say about each component's selectivity?

Raun et al. characterized ipamorelin as the first highly selective GH secretagogue, releasing GH with minimal effect on cortisol, prolactin, or ACTH. Teichman et al. characterized CJC-1295 as raising mean GH and IGF-1 with persistence of pulsatile secretion. The blend pairs CJC-1295's GHRH-arm drive with ipamorelin's clean ghrelin-arm signal.

Is this blend FDA-approved?

No. Neither component nor the combination is an FDA-approved drug, and the blend is supplied strictly for in-vitro and laboratory research use only with no human concentration. The literature describes experimental GH/IGF-1 axis pharmacology. Each research lot should ship with a Certificate of Analysis documenting purity and identity.

Is CJC-1295 + Ipamorelin legal to buy for research?

CJC-1295 + Ipamorelin is sold in the United States as a research chemical for laboratory and in-vitro use only. It is not approved by the FDA for human use and is not sold for human consumption. Researchers are responsible for compliance with all applicable federal, state, and institutional regulations.

Does CJC-1295 + Ipamorelin come with a Certificate of Analysis?

Yes. Every batch of CJC-1295 + Ipamorelin from Elyte Peptides ships with a third-party Certificate of Analysis (COA) documenting identity and HPLC purity (≥98%), so research results can be traced to a verified lot.

What is CJC-1295 + Ipamorelin and how does it work?

This combination pairs two distinct growth hormone secretagogues that work through complementary mechanisms. CJC-1295 (without DAC) is a modified GHRH analogue that stimulates GH release from pituitary somatotrophs via the GHRH receptor. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist. Together, they amplify GH pulsatility through dual-pathway stimulation while maintaining selectivity — ipamorelin does not significantly affect cortisol or prolactin levels.

What research has been done on CJC-1295 + Ipamorelin?

CJC-1295 research published in the Journal of Clinical Endocrinology & Metabolism demonstrated sustained GH and IGF-1 elevation with a favorable safety profile. Ipamorelin studies (European Journal of Endocrinology) showed selective GH release without significant hunger, cortisol, or prolactin side effects. The combination has been studied in preclinical models for synergistic GH amplification, with results suggesting greater GH AUC than either peptide alone.

How does CJC-1295 + Ipamorelin compare to GHRP-6?

The key advantage of ipamorelin over GHRP-6 is selectivity. GHRP-6 activates ghrelin receptors broadly, causing significant increases in appetite, cortisol, and prolactin. Ipamorelin is among the most selective GH secretagogues, stimulating GH release with minimal impact on other hormones. When combined with CJC-1295, it provides a cleaner research model for studying GH-specific effects without confounding hormonal variables.

Research References

All research guides